Samsung Biologics Co.,Ltd. (KRX: 207940)

Market Cap	73.74T
Revenue (ttm)	4.21T
Net Income (ttm)	1.03T
Shares Out	71.17M
EPS (ttm)	14,449.16
PE Ratio	71.70
Forward PE	65.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,649
Open	1,011
Previous Close	995,000
Day's Range	992,000 - 1,033
52-Week Range	694,000 - 1,109
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality ass...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,523
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2023, Samsung Biologics Co.,Ltd.'s revenue was 3.69 trillion, an increase of 23.10% compared to the previous year's 3.00 trillion. Earnings were 857.69 billion, an increase of 7.47%.